| Date Filed | Type | Description |
| 09/28/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/15/2023 |
SC 13D/A
| PERCEPTIVE ADVISORS LLC reports a 22.1% stake in Soleno Therapeutics, Inc. |
| 06/06/2023 |
SC 13D/A
| PERCEPTIVE ADVISORS LLC reports a 27% stake in Soleno Thereputics, Inc. |
| 05/25/2023 |
SC 13D/A
| PERCEPTIVE ADVISORS LLC reports a 23.8% stake in Soleno Thereputics, Inc. |
| 05/18/2023 |
SC 13D
| PERCEPTIVE ADVISORS LLC reports a 22.8% stake in Soleno Thereputics, Inc. |
| 05/16/2023 |
SC 13D/A
| PERCEPTIVE ADVISORS LLC reports a 19.1% stake in MeiraGTx Holdings plc |
| 05/04/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/25/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/21/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 04/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/14/2023 |
SC 13G
| PERCEPTIVE ADVISORS LLC reports a 8.9% stake in Bellerophon Therapeutics, Inc. |
| 03/07/2023 |
SC 13G
| PERCEPTIVE ADVISORS LLC reports a 6.5% stake in Reata Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 0% stake in Neptune Wellness Solutions Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 0% stake in Research Alliance Corp. II |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 9.3% stake in Rain Oncology Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 12.3% stake in Verrica Pharmaceuticals Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 7.6% stake in Inhibrx, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 3.8% stake in Mirati Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 3.6% stake in Concert Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 2.6% stake in Prometheus Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 9.2% stake in Amylyx Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 4.9% stake in Tarsus Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 10% stake in IsoPlexis Corporation |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 14.4% stake in Acrivon Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 0.4% stake in IVERIC bio, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 19.4% stake in Aldeyra Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 6.3% stake in Iovance Biotherapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 7.1% stake in Bellus Health Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 7.2% stake in Zymeworks Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 9.9% stake in enVVeno Medical Corporation |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 9.8% stake in Amicus Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 5.3% stake in RAPT Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| PERCEPTIVE ADVISORS LLC reports a 5.5% stake in Arcellx, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 5.4% stake in ADMA Biologics, Inc. |
|